Fortunately, our study in vivo demonstrated that the therapy of CQCQD significantly decreased the levels of sera amylase and plasma LPS, Lbp, and Cd14 compared to that in SAP group (Table 3), which suggested that the therapy of CQCQD could attenuate the increase in the upstream trigger molecules caused by SAP complicated by endotoxemia. The gene discussed is LBP; the disease is serum lipopolysaccharide activity.